Base Year
Historical Year
Forecast Year
The global HUMIRA (Adalimumab) drug market is expected to witness significant growth during the forecast period of 2024-2032, driven by the increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment. The market is projected to grow at a CAGR of 1% during the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global HUMIRA (Adalimumab) drug market is a rapidly growing market that provides treatment for various autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. HUMIRA is a biologic drug that works by suppressing the immune system and reducing inflammation. It is a widely used drug and is considered as a first-line treatment option for many autoimmune diseases. The increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment are the key drivers of the market.
Expert Market Research has released a comprehensive report on the global HUMIRA (Adalimumab) drug market, which provides an in-depth analysis of the market and its segments. HUMIRA is a widely used drug for the treatment of various autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, psoriasis, and ulcerative colitis. The report covers the market for HUMIRA and provides a detailed analysis of the market size, growth, and trends. The market is highly competitive with several key players involved in the market, focusing on developing new drugs and therapies to strengthen their position in the market.
The global HUMIRA (Adalimumab) drug market is used for the treatment of various autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. HUMIRA is a biologic drug that works by targeting and reducing the activity of a specific protein called tumor necrosis factor-alpha (TNF-alpha) that is involved in causing inflammation in the body. The drug is administered subcutaneously or intravenously, depending on the condition being treated.
Rheumatoid arthritis is one of the primary applications of HUMIRA, and it is widely used as a first-line treatment option for this condition. It is also used for the treatment of psoriasis, which is a chronic skin condition characterized by red, scaly patches on the skin. HUMIRA can provide relief from the symptoms of psoriasis by reducing inflammation in the skin.
In addition to rheumatoid arthritis and psoriasis, HUMIRA is also used for the treatment of Crohn's disease and ulcerative colitis. These are chronic inflammatory bowel diseases that affect the digestive system. HUMIRA can help reduce inflammation in the digestive tract and improve symptoms such as abdominal pain, diarrhea, and rectal bleeding.
The market can be categorised into indication, type, dosage strength, drug type, distribution channel, and route of administration.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Indication
Market Breakup by Type
Market Breakup by Dosage Strength
Market Breakup by Drug Type
Market Breakup by Distribution Channels
Market Breakup by Route of Administration
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global HUMIRA (Adalimumab) drug market is expected to witness significant growth during the forecast period of 2024-2032. The market is driven by the increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment.
North America dominates the HUMIRA drug market, followed by Europe and the Asia Pacific region. The high prevalence of autoimmune diseases and the availability of advanced healthcare infrastructure are driving the growth of the market in North America. Europe is also a significant market for HUMIRA, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.
In addition, the COVID-19 pandemic has also affected the HUMIRA drug market, with disruptions in supply chain and manufacturing activities. However, the market is expected to recover in the post-pandemic period, driven by the increasing demand for effective treatments for autoimmune diseases.
Overall, the global HUMIRA (Adalimumab) drug market is expected to continue its growth trajectory during the forecast period, offering numerous opportunities for key players and investors in the industry.
The report gives an in-depth analysis of the key players involved in the HUMIRA (Adalimumab) drug market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication |
|
| Breakup by Type |
|
| Breakup by Dosage Strength |
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The prevalence rate of global HUMIRA (Adalimumab drug) market is likely to grow at a CAGR of 1% during the forecast period of 2024-2032.
Asia Pacific region has the highest growth rate in the HUMIRA (Adalimumab drug) market.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market.
North America dominated the HUMIRA (Adalimumab drug) market and is expected to grow during the forecast period due to excellent healthcare infrastructure, effective government policies, large base of multinational corporations, and high public awareness about diagnosis and medical assistance.
AbbVie Inc., Amgen Inc., Fresenius Kabi AG, Celltrion Healthcare Co Ltd, Alvotech Ehf., Bio-Thera Solutions Ltd., Cadila Healthcare Ltd., Hetero Healthcare Ltd., Innovent Biologics, Inc., Novartis International AG are the key companies in the global HUMIRA (Adalimumab drug) market.
The factors stimulating the development of the market include increased government initiatives, optimal costs, and a rise in R&D expenditure in biopharmaceutical companies.
The high cost of clinical trials and research and development represents a major challenge for market participants. Despite heavy R&D spending, manufacturers must keep their products low, which limits growth opportunities in the HUMIRA market.
IBI303 and CT-P17 are the emerging drugs that will appear in the market
HUMIRA is a medicine used to treat ankylosing spondylitis, rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ulcerative colitis, hidradenitis suppurativa and other diseases affecting the musculoskeletal system.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share